If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...